Efficacy and safety of induction chemotherapy in oral cavity cancer: An eight-year experience at a Portuguese reference center

被引:0
|
作者
Barbosa-Martins, Joao [1 ]
Rolo, Ana [1 ]
Lima, Barbara [1 ]
Pereira, Jose Carlos [2 ]
Araujo, Claudia [2 ]
Guimaraes, Jorge [2 ]
Dinis, Jose [3 ]
Vieira, Claudia [3 ]
机构
[1] Hosp Senhora Oliveira, Med Oncol Dept, R Cutileiros 114, P-4835044 Guimaraes, Portugal
[2] Inst Portugues Oncol Porto Francisco Gentil, Surg Oncol, Porto, Portugal
[3] Inst Portugues Oncol Porto Francisco Gentil, Med Oncol Dept, Porto, Portugal
来源
TUMORI JOURNAL | 2024年 / 110卷 / 05期
关键词
Oral cavity cancer; squamous cell carcinoma; induction chemotherapy; toxicity; surgery; radiotherapy; PHASE-III TRIAL; NEOADJUVANT CISPLATIN; FLUOROURACIL; SURGERY; HEAD; DOCETAXEL;
D O I
10.1177/03008916241257099
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Induction chemotherapy has been described as an option in locally advanced oral cavity squamous cell carcinoma when the surgical morbidity is expected to be high. This work aimed to evaluate the outcome and safety of induction chemotherapy in this setting. Methods: We performed a retrospective and observational study including patients with oral cavity squamous cell carcinoma, treated with induction chemotherapy between January 2010 and December 2018. Outcomes included induction chemotherapy toxicity, treatment response, disease-free survival and overall survival. Results: A total of 108 oral cavity squamous cell carcinoma patients were included. Ninety-six (88.9%) had stage IV disease, while 12 (11.1%) had stage III. Eighty-four patients (80.8%) achieved at least a partial response to induction chemotherapy at clinical evaluation, and 75 (72.1%) at radiological evaluation. Seventy-eight patients have been proposed for subsequent definitive treatments, with no differences obtained in prognosis, when comparing surgical to non-surgical approaches. In patients treated with definitive treatments, improved five-year disease-free survival was obtained if at least a clinical (56.3%; p=0.001) or radiological (52.9%; p=0.001) partial response was achieved after induction chemotherapy. Similarly, superior five-year overall survival was verified for those achieving at least clinical (51.1%; p<0.0001) or radiological (52.6%; p=0.001) partial response. Also, accomplishing a pathologic complete response (n=22.6%) significantly improved disease-free survival (p=0.039) and overall survival (p=0.005). Grade 3 and 4 toxicities were observed in 52 patients (41.8%). Conclusion: Responses to induction chemotherapy predicted prognosis in our population, however important toxicities were observed. Further studies are necessary to identify induction chemotherapy response predictors and subgroups who may benefit from this approach.
引用
收藏
页码:340 / 347
页数:8
相关论文
共 50 条
  • [21] Response to induction chemotherapy as predictive marker of tumor response to radiotherapy and survival in oral cavity cancer
    Saini, Surendra Kumar
    Srivastava, Shelly
    Prasad, Shanbhu Nath
    CLINICAL CANCER INVESTIGATION JOURNAL, 2015, 4 (04): : 520 - 524
  • [22] Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: Eight-year experience
    Uchida, Toyoaki
    Shoji, Sunao
    Nakano, Mayura
    Hongo, Satoko
    Nitta, Masahiro
    Murota, Akiko
    Nagata, Yoshihiro
    INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (11) : 881 - 886
  • [23] Outcomes of Radical Radiotherapy (RT) or Chemoradiotherapy (CRT) in Surgically Inoperable Advanced Oral Cavity Cancer: A Single Center Experience
    Shenoy, Shashank
    Mallick, Ankita
    Pati, Sudipta
    Chatterjee, Sanjoy
    Mallick, Indranil
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, : 1447 - 1454
  • [24] Results of a prospective randomized trial with induction chemotherapy for cancer of the oral cavity and tonsils
    Volling, P
    Schröder, M
    Eckel, H
    Ebeling, O
    Stennert, E
    HNO, 1999, 47 (10) : 899 - 906
  • [25] Sentinel node biopsy for early-stage oral cavity cancer: the VU University Medical Center experience
    Den Toom, Inne J.
    Heuveling, Derrek A.
    Flach, Geke B.
    van Weert, Stijn
    Karagozoglu, K. Hakki
    van Schie, Annelies
    Bloemena, Elisabeth
    Leemans, C. Rene
    de Bree, Remco
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2015, 37 (04): : 573 - 578
  • [26] Parameters of Stromal Activation and Epithelial to Mesenchymal Transition as Predictive Biomarkers for Induction Chemotherapy in Patients With Locally Advanced Oral Cavity and Oropharyngeal Squamous Cell Cancer
    Geweiler, Jana
    Inhestern, Johanna
    Berndt, Alexander
    Guntinas-Lichius, Orlando
    Clinical and Experimental Otorhinolaryngology, 2016, 9 (04) : 374 - 381
  • [27] PRELIMINARY-RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL WITH INDUCTION CHEMOTHERAPY FOR CANCER OF THE ORAL CAVITY AND PHARYNX
    VOLLING, P
    SCHRODER, M
    HNO, 1995, 43 (02) : 58 - 64
  • [28] Screening for Oral Cavity Cancer: A 1-year Experience of a Regional Hospital in Taiwan
    Chi, Tzu-Hang
    Yuan, Chien-Han
    Chen, Rong-Feng
    JOURNAL OF NEPAL MEDICAL ASSOCIATION, 2014, 52 (11) : 902 - 906
  • [29] Efficacy and Safety of Single Agent or Combination Adjuvant Chemotherapy in Elderly Patients With Colon Cancer: A Canadian Cancer Institute Experience
    Kim, Christina A. K.
    Spratlin, Jennifer L.
    Armstrong, Dawn E.
    Ghosh, Sunita
    Mulder, Karen E.
    CLINICAL COLORECTAL CANCER, 2014, 13 (03) : 199 - 206
  • [30] Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience
    Muranaka, Tetsuhito
    Yuki, Satoshi
    Komatsu, Yoshito
    Sawada, Kentaro
    Harada, Kazuaki
    Kawamoto, Yasuyuki
    Nakatsumi, Hiroshi
    Sakamoto, Naoya
    JOURNAL OF GASTRIC CANCER, 2016, 16 (03) : 177 - 181